USE OF TUMOR MARKERS IN POSTOPERATIVE PROGNOSIS OF NON-SMALL-CELL LUNG CANCER

USE OF TUMOR MARKERS IN POSTOPERATIVE PROGNOSIS OF NON-SMALL- CELL LUNG CANCER Introduction: The most frequently used prognostic parameters in clinical practice of NSCLC are disease stadium and affection of hilar or mediastinal lymph nodes. These phactors are not sufficient and therefore new prognostic parameters - tumor markers - are being searched for. Tumor markers regarding NSCLC have mainly been used so far to monitore effects of medical treatment or detection of carcinoma recurrency. The study concentrates on assessment of tumor markers significance for NSCLC. Methods: The total group includes 125 patients operated on for NSCLC in the years 2004-2007. Single groups of patients were assessed successively. Serum markers CYFRA 21-1, CEA, TK, TPS, and NSE were assessed in an immunoanalytical way in 34 patients: Serum parameters of angiogenesis through Luminex® xMAP® technology were assessed in 27 patients. Serum values of cytokeratins were assessed in an immunoanalytical way with 125 patients. Expressions of metalloproteinases (MMP-7, MMP-9) and their inhibitors (TIMP-1, TIMP-2) were assessed in NSCLC tissue with 91 patients and in lung tissue with 12 patients with benign pulmonary disease. Finally, OS and DFI were assessed in accordance with tissue expression of metalloproteinases and their..